Cansino is in the final stage of trial and already approved to be put into use for Chinese military snd others .will be approved by other countries any moment from now
_____________________________________________
Inside the CanSino Phase 3 COVID-19 vaccine trial at Pakistan’s Shifa Hospital BENAZIR SHAH
LAHORE: Doctors in green scrubs and sneakers darted in and out of specially designated rooms at Shifa International Hospital in Islamabad one chilly morning last month, attending to volunteers participating in late-stage clinical trials for a Chinese coronavirus vaccine.
Pakistan launched the trial in September for Ad5-nCoV, a vaccine candidate co-developed by CanSino Biologics and a Chinese military-backed research unit. The tests are being led by Pakistan’s National Institute of Health (NIH) and the Chinese company’s local representative.
This month’s announcement by Pfizer that its experimental COVID-19 vaccine was more than 90 percent effective based on initial trial results has been hailed as a major victory in the war against a virus that has killed more than a million people and battered the world’s economy.
Though scientists, public health officials and investors have welcomed the first successful interim data from a large-scale clinical test as a watershed moment, they also say several vaccines will be necessary to meet massive global needs.
In Pakistan, the government plans to administer the experimental Chinese vaccine to at least 10,000 volunteers, doctors in charge of the program said.
Shifa International, the first of five trial sites, has repurposed a building previously used for COVID-19 testing for the trial. There are two more trial centers in Karachi and two in Lahore.
“There is a criterion that each volunteer has to fulfil,” Dr. Ejaz Khan, the chairman of infection control at Shifa Hospital, told Arab News.
Volunteers can arrive by appointment, or simply walk in, but must be over 18 years of age, willing to participate, have no major diseases and not have been infected with the coronavirus, Khan, who is heading the trials, said. Pregnant women cannot take part in the exercise.
“Also, he or she must be able to participate for more than one year,” Khan said.
Doctors administering the trials said that they had to ensure that each volunteer was first counselled on what to expect from the process, asked to sign a document of consent and have his or her basic health examined. Next, blood samples were taken, and then the vaccine was injected into the upper arm.
Since Sept. 22, Khan said 1,500 people had taken part in the trial at Shifa Hospital where doctors work from 9 a.m. to 5 p.m. every day to register volunteers’ data and store their samples.
During the year’s course, the volunteers will be monitored through weekly messages and monthly phone calls.
Each participant receives a one-time travel and food allowance of 3,000 Pakistani rupees ($19) on the first visit and 5,000 Pakistani rupees on the second, a year later, when he or she must provide a second blood sample.
Last month, sisters Urmila, 18, and Faiza, 20, who had arrived to volunteer for the trials, said that they had heard about the trial from a neighbor, who told them that each candidate would receive a travel allowance.
“Yes that (the money) is one reason,” said Urmila when asked why she was volunteering, holding her national identity card, a pen and a questionnaire in her hands.
The form required basic contact details and a brief health history to be filled out before a candidate could be approved for the trial. “I don’t know what to write,” Urmila said. “I am not literate, you see.”
Seated behind her was Sumaira Shafiq, a middle-aged housewife who unlike Urmila was still unsure about whether she should participate in the trial. “I am observing right now,” she said. “Who knows, I might just slip out before my turn.”
If Shafiq ends up participating in the trial, her blood samples, like those of all participants, will be shipped to Dalhousie University in Canada, which will independently review the data to determine the vaccine’s efficacy.
By early next year, interim results are expected to become available.
“Let’s say three months from now, they (the university) will tell us OK this vaccine is not effective, stop the trials, or the vaccine is effective, let’s move to Phase 4,” Khan said.
Phase 4 is when the vaccine will be prepared for manufacturing, marketing and distribution.
Pakistani officials have said once proven, they expect Pakistan will be provided with several million doses of the vaccine on a priority basis by CanSinoBio.
The Chinese vaccine, one of nine developed worldwide that are considered safe, will be tested on 40,000 people in several countries.
So far only 10 percent of the participants have developed adverse reactions to the vaccine. “These include pain in the injection area,
CanSino Biologics Inc.’s Russian partner expects local authorities to register the Chinese company’s Covid-19 vaccine soon, potentially marking the first approval for use of the inoculation outside of China.
“All registration procedures have been completed, we expect to get the registration certificate in days,” Nikolay Dodonov, head of Petrovax Pharm’s medical department, said in a phone interview.
The CanSino vaccine is currently undergoing Phase 3 trials and has been granted military approval in China, which is more limited than emergency authorization.
Pakistan Trial .....News from September 2020, and until today no progress....says a lot in efficacy and competency. Shouldn't the chinese military be marching on with deadlines and sitrep? (Situation report)
Cont’d ———— The company is nearing a goal of recruiting 18,000 people in a trial in Pakistan, and is close to conducting interim analysis that will offer a first glimpse at how effective the shot can be in staving off Covid-19.
Russia is among the first countries to offer universal access to Covid-19 vaccines, with President Vladimir Putin this week ordering authorities to let anyone who wants sign up for an inoculation. It currently has two domestic vaccines registered for use.
Petrovax, owned by the country’s richest man, Vladimir Potanin, got permission for a local Phase 3 trial of the CanSino vaccine in August and applied to register it in November, according to Dodonov.
Petrovax completed injections of 500 volunteers in its local trial in November and has analyzed the results of 200 so far, Dodonov said. Of those assessed, 149 received the inoculation and had antibody levels four times higher than the minimum threshold for immunity, he said.
Petrovax, which is also helping conduct CanSino’s international trial in Russia, plans to complete its study by May.
Solution Group Bhd has obtained shareholders approval to diversify into pharmaceutical-related business at its EGM on Friday.
Its wholly-owned subsidiary Solution Biologics Sdn Bhd (SolBio) on Sept 23 entered into an agreement with CanSino Biologics Inc for both parties to collaborate on the manufacturing and commercialisation of the latter’s Covid-19 vaccine.
It has also obtained approval from the Health Ministry’s National Pharmaceutical Regulatory Agency for a design plan and layout of its vaccine fill and finish facility.
whatever news whether is real or fake. janji dapat duit raya. yang lain tu tak mau kira lah. ada vaksin takda vaksin kenapa nak kesah sangat. kesah your bet make sure win win not lose more important. no one bother whether you win or lose they only bother their own bet is win only. betul?
katak promoter your friend at lambo very hypocrite lah. he also anti solution yet you still so close to the akar boy kah. next time dont trust what akar boy say lah. he is penipu hypocrite and fitnH king lah. you follow him and behave like him kah. correct?
Posted by scenery > Aug 24, 2020 9:33 PM | Report Abuse
They are still testing the vaccine, if fail then all gg, not ready yet sign what MOU?
MOU is nothing, anytime also can cancel without having to pay compensation if not successful.
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
UlarSawa
35,552 posts
Posted by UlarSawa > 2021-01-17 13:07 | Report Abuse
wait khairy announce baru real. correct?